The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.
S. Verma
Honoraria - GlaxoSmithKline; Roche
Research Funding - Roche; Sanofi
V. Dieras
Consultant or Advisory Role - Eisai; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche (U); Sanofi
Honoraria - Eisai; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
L. Gianni
Consultant or Advisory Role - Boehringer Ingelheim; Eisai; Genentech; GlaxoSmithKline; Merrimack; Pfizer; Roche; Wyeth
D. Miles
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche
M. Welslau
No relevant relationships to disclose
M. D. Pegram
Consultant or Advisory Role - Takeda (U)
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - Sanofi
Expert Testimony - Novartis (U)
Other Remuneration - Bristol-Myers Squibb; Pfizer; Roche/Genentech
J. Baselga
No relevant relationships to disclose
E. Guardino
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
L. Fang
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
C. M. Linehan
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
K. L. Blackwell
Consultant or Advisory Role - Genentech